These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 23867515)

  • 1. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
    Ramakrishnan S; Pili R
    Cancer J; 2013; 19(4):333-40. PubMed ID: 23867515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in prostate cancer: biologic and clinical relevance.
    Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
    Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer.
    Xiao Y; Su M; Ou W; Wang H; Tian B; Ma J; Tang J; Wu J; Wu Z; Wang W; Zhou Y
    Biomed Pharmacother; 2019 Sep; 117():109192. PubMed ID: 31387188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic regulation and cancer (review).
    Chen QW; Zhu XY; Li YY; Meng ZQ
    Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
    Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
    Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications.
    Silverman BR; Shi J
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27999365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
    Maleszewska M; Kaminska B
    Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulated chromatin remodeling in the pathobiology of brain tumors.
    Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
    Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone modifications: implications in renal cell carcinoma.
    Ramakrishnan S; Ellis L; Pili R
    Epigenomics; 2013 Aug; 5(4):453-62. PubMed ID: 23895657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
    Bhalla KN
    J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromatin remodeling and histone modifications in pituitary tumors.
    Tateno T; Zhu X; Asa SL; Ezzat S
    Mol Cell Endocrinol; 2010 Sep; 326(1-2):66-70. PubMed ID: 20060434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of chromatin remodeling and DNA damage in stem cells induced by environmental and dietary agents.
    Bariar B; Vestal CG; Richardson C
    J Environ Pathol Toxicol Oncol; 2013; 32(4):307-27. PubMed ID: 24579784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer.
    Walsh L; Gallagher WM; O'Connor DP; Ní Chonghaile T
    Expert Rev Mol Diagn; 2016; 16(5):541-51. PubMed ID: 26895288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetics of Huntington's Disease.
    Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
    Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic alterations during renal carcinogenesis.
    Arai E; Kanai Y
    Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.